Use of Autoantibodies to Detect the Onset of Breast Cancer

Figure 1

Breast cancer autoantibody research pipeline. Methodologies for identification of TAAs consist to locate specific immunogenic proteins specific from a source of antigens (recombinant protein or extracted from cell cultures or tumors). Different screening methods have been developed in order to identify TAAs such as SEREX (serological identification of antigens by recombinant expression cloning), SERPA (serological proteome analysis), or more recently microarray. TAAs were subsequently evaluated and validated using ELISA on multiplex methodologies such as Luminex or microarray. DCIS (ductal carcinoma in situ); LCIS (lobular carcinoma in situ); PBC (primary breast cancer); IBC (invasive breast cancer); HC (healthy control); BBL (benign breast lesions); AID (autoimmune disease); AUC (area under curve).